10x Genomics (TXG) reported $643M in revenue for fiscal 2025, +5.2% year on year. That ranks #2063 by revenue among 2853 SEC filers and #376 in Technology. It posted a net loss of −$43.5M for the same year. Revenue has grown 31.7% a year on average since 2017 ($71.1M then). The fiscal 2025 balance sheet shows $1.0B in total assets, $474M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $643M | +5.2% | FY20252025-12-31 |
| Gross profitGrossProfit | $444M | +7.1% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$61.0M | +$134M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$43.5M | +$139M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $136M | +1,941.6% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $5.9M | −52.1% | FY20252025-12-31 |
| Total assetsAssets | $1.0B | +13.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $796M | +12.1% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $474M | +37.8% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $0 | −100.0% | FY20202020-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $151M | −$13.5M | Open → |
| Q2 20262026-06-30 | $151M | −$17.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- 10x Genomics, Inc.
- Ticker
- TXG
- Exchange
- Nasdaq
- SIC classification
- Laboratory Analytical Instruments (3826)
- Fiscal year end
- 12-31
- CIK
- 0001770787
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 13, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Kulicke & Soffa IndustriesKLIC | $654M | $213,000 |
| Universal DisplayOLED | $651M | $242M |
| DoximityDOCS | $645M | $196M |
| 10x GenomicsTXG | $643M | −$43.5M |
| MarqetaMQ | $625M | −$13.9M |
| FastlyFSLY | $624M | −$122M |
| Varonis SystemsVRNS | $624M | −$129M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=10x Genomics — Key figures |url=https://companiesranked.com/en/company/10x-genomics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). 10x Genomics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/10x-genomicsBibTeX
@misc{companiesranked-en-company-10x-genomics-2026,
author = {{CompaniesRanked}},
title = {{10x Genomics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/10x-genomics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-007822 · February 13, 2026
{{cite web |title=10x Genomics — Key figures — 10-K (0001628280-26-007822) |url=https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-13}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.